Brazil was the first Latin American country to make ivacaftor available in the public health system for cystic fibrosis patients older than 6 years having one of nine class III CFTR variants, or patients older than 18 years with an R117H causing variant. This evidence concerns the gene CFTR and cystic fibrosis.